Covishield

#GS3 #COVID-19 

Covishield, the vaccine candidate from the Pune-based Serum Institute of India, was approved by a subject expert committee (SEC) of the Drugs Controller General of India (DCGI).

  • Bharat Biotech has been asked to furnish more data demonstrating the efficacy of its candidate, Covaxin.
  • Covishield is likely to be practically available for use within the next week. Similar to that in the United Kingdom, have approved the vaccine to be given in two doses 4-12 weeks apart.
  • Covishield, which is similar to the ‘Oxford vaccine’ developed by the Oxford University vaccine group and marketed by AstraZeneca, was approved by the health regulator in the U.K. under emergency use conditions. 
  • Cheaper and easier to distribute than rival vaccines, the Oxford-AstraZeneca COVID-19 vaccine is by far the most significant vaccine against coronavirus.
  • India's drug regulator is set to approve a coronavirus vaccine developed by Oxford University and AstraZeneca, for emergency use.
  • Dubbed as Covishield in India, the Oxford-AstraZeneca COVID-19 vaccine showed an average efficacy of 70.4%, with no hospitalisations or severe disease, according to the data. 
  • The vaccine is "virus-vectored", which means it is a version of a virus that normally infects chimpanzees and has been modified with a portion of the COVID-19 called the "spike protein" to fire the immune system. 
  • Once in human cells, the vaccine should help stimulate the production of antibodies that recognize the virus.
  • Cheaper and easier to distribute than rival vaccines, the Oxford-AstraZeneca COVID-19 vaccine is by far the most significant in the global fight against the novel coronavirus. 
  • Unlike the two messenger RNA vaccines by US firms Pfizer and Moderna, this vaccine could be kept at normal refrigerator temperatures of between two and eight degrees Celsius.
  • The Moderna vaccine needs to be stored at -20C, while the Pfizer/BioNTech product must be kept at -70C. It will be priced as little as $3 per dose.
  • Researchers claimed the vaccine protected against disease in 62% of those given two full doses and in 90% of those initially given a half dose.
  • The world's biggest producer of vaccines, has already stockpiled about 50 million doses, enough for 25 million people. 
  • The COVID-19 vaccine will be distributed initially in India, then to the COVAX countries which are mainly in Africa. Our priority is India & COVAX countries.
  • India's Central Drugs Standard Control Organization (CDSCO) could also approve a vaccine locally developed by Bharat Biotech. 
Print Friendly and PDF
blog comments powered by Disqus